Pharmacological Intervention to Modulate HDL: What Do We Target?

Area of Science:

• Cardiovascular Disease Research
• Lipid Metabolism and Atherosclerosis

Background:

• Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol levels are traditional cardiovascular disease risk factors.
• Therapeutic strategies to increase HDL cholesterol have yielded limited success in improving cardiovascular outcomes.
• The heterogeneity of HDL particles, including subclasses and diverse functions, complicates the interpretation of HDL cholesterol quantity.

Purpose of the Study:

• To review current data on HDL subclasses and their specific functionalities.
• To evaluate the impact of common lipid-modifying drugs on HDL subclasses.
• To explore the potential differential protective effects of HDL subclasses, specifically HDL3 versus HDL2.

Main Methods:

• Literature review of existing clinical and scientific data on HDL subclasses and function.
• Analysis of how lipid-modifying drugs (statins, CETP inhibitors, fibrates, niacin) affect HDL subclasses.
• Comparative assessment of protective roles attributed to HDL2 and HDL3 subclasses.

Main Results:

• Many clinical trials show increased HDL cholesterol without a reduction in cardiovascular events.
• Lipid-modifying drugs often increase cholesterol in specific HDL subclasses.
• Emerging evidence suggests HDL3 may confer greater cardioprotective benefits than HDL2.

Conclusions:

• HDL cholesterol quantity may be an insufficient marker for cardiovascular risk.
• Future therapeutic strategies should consider HDL subclass and function over total cholesterol levels.
• The HDL3 subclass shows promise for enhanced cardiovascular protection.